Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Rituximab
MabThera
Routinely available
SMC (591/09)
20/04/2011
Indication
Relapsed/refractory CLL
Therapeutic Area
Malignant disease and immunosuppression
Status Description
Routinely available
Formulation
100mg, 500mg concentrate for solution for infusion
Comments
April 2011 - Added to the Additional List, Specialist Use only.